These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 14743544)

  • 1. Pilot clinical trial of the use of alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis.
    Takagi H; Kakizaki S; Sohara N; Sato K; Tsukioka G; Tago Y; Konaka K; Kabeya K; Kaneko M; Takayama H; Hashimoto Y; Yamada T; Takahashi H; Shimojo H; Nagamine T; Mori M
    Int J Vitam Nutr Res; 2003 Nov; 73(6):411-5. PubMed ID: 14743544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients.
    Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Tanaka J
    J Gastroenterol Hepatol; 2013 Feb; 28(2):357-64. PubMed ID: 23190084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
    Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
    Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
    Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of child stage A.
    Tarao K; Rino Y; Ohkawa S; Endo O; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Nagaoka T; Okamoto N; Tanaka K; Tarao N
    Intervirology; 2004; 47(2):65-71. PubMed ID: 15192269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
    Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
    Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].
    Petry W; Heintges T; Hensel F; Erhardt A; Wenning M; Niederau C; Häussinger D
    Z Gastroenterol; 1997 Dec; 35(12):1059-67. PubMed ID: 9487638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis.
    Miyakawa K; Tarao K; Ohshige K; Morinaga S; Ohkawa S; Okamoto N; Shibuya A; Adachi S; Miura Y; Fujiyama S; Miyase S; Tomita K
    Scand J Gastroenterol; 2009; 44(11):1340-8. PubMed ID: 19891585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative-inflammatory damage in cirrhosis: effect of vitamin E and a fermented papaya preparation.
    Marotta F; Yoshida C; Barreto R; Naito Y; Packer L
    J Gastroenterol Hepatol; 2007 May; 22(5):697-703. PubMed ID: 17444858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
    Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis.
    Sato A; Kato Y; Nakata K; Nakao K; Daikoku M; Ishii N; Matsumoto T; Iseki K; Mazume H; Nagataki S
    J Gastroenterol Hepatol; 1996 Oct; 11(10):944-8. PubMed ID: 8912132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of simple non-invasive liver fibrosis indices for predicting hepatocellular carcinoma (HCC) among Egyptian patients.
    Abdelgawad IA
    J Clin Pathol; 2015 Feb; 68(2):154-60. PubMed ID: 25430496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections.
    Kobayashi M; Ikeda K; Hosaka T; Sezaki H; Someya T; Akuta N; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Miyakawa Y; Kumada H
    J Med Virol; 2006 Apr; 78(4):459-65. PubMed ID: 16482557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An analysis of clinical characteristics and risk factors of cirrhosis-related hepatocellular carcinomas in patients with hepatitis C virus infection].
    Wu CH; Tian GS; Xu XY; Yu YY; Huang T
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):210-4. PubMed ID: 18364082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.
    Ikeda K; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Murashima N; Chayama K; Kumada H
    J Gastroenterol Hepatol; 2001 Apr; 16(4):406-15. PubMed ID: 11354279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
    Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
    Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.